Published in Pflege Z on February 01, 2002
Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer. J Clin Oncol (2006) 6.07
MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell (2009) 4.47
ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59
Inhibition of growth and metastasis of mouse mammary carcinoma by selective inhibitor of transforming growth factor-beta type I receptor kinase in vivo. Clin Cancer Res (2006) 2.01
Alterations of Smad signaling in human breast carcinoma are associated with poor outcome: a tissue microarray study. Cancer Res (2002) 1.69
Smad2 and Smad3 play different roles in rat hepatic stellate cell function and alpha-smooth muscle actin organization. Mol Biol Cell (2005) 1.65
A prototype for unsupervised analysis of tissue microarrays for cancer research and diagnostics. IEEE Trans Inf Technol Biomed (2004) 1.55
Amelioration of radiation-induced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J Biol Chem (2004) 1.46
Targeting the Transforming Growth Factor-beta pathway inhibits human basal-like breast cancer metastasis. Mol Cancer (2010) 1.45
Breast cancer prognosis by combinatorial analysis of gene expression data. Breast Cancer Res (2006) 1.43
TGFBR1*6A and cancer: a meta-analysis of 12 case-control studies. J Clin Oncol (2004) 1.42
Transforming growth factor-beta signaling: emerging stem cell target in metastatic breast cancer? Breast Cancer Res Treat (2008) 1.41
ImageMiner: a software system for comparative analysis of tissue microarrays using content-based image retrieval, high-performance computing, and grid technology. J Am Med Inform Assoc (2011) 1.40
Gene expression profiling changes induced by a novel Gemini Vitamin D derivative during the progression of breast cancer. Biochem Pharmacol (2006) 1.37
Loss of Smad signaling in human colorectal cancer is associated with advanced disease and poor prognosis. Cancer J (2003) 1.35
Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. Cancer Res (2004) 1.29
Ovarian cancer detection by logical analysis of proteomic data. Proteomics (2004) 1.28
Insulin-like growth factor-I inhibits transcriptional responses of transforming growth factor-beta by phosphatidylinositol 3-kinase/Akt-dependent suppression of the activation of Smad3 but not Smad2. J Biol Chem (2003) 1.23
TLP, a novel modulator of TGF-beta signaling, has opposite effects on Smad2- and Smad3-dependent signaling. EMBO J (2003) 1.16
Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype. Cancer Res (2008) 1.14
Transforming growth factor-beta 1 regulation of collagenase-3 expression in osteoblastic cells by cross-talk between the Smad and MAPK signaling pathways and their components, Smad2 and Runx2. J Biol Chem (2004) 1.14
Unsupervised imaging, registration and archiving of tissue microarrays. Proc AMIA Symp (2002) 1.05
Betaglycan inhibits TGF-beta signaling by preventing type I-type II receptor complex formation. Glycosaminoglycan modifications alter betaglycan function. J Biol Chem (2001) 1.02
Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One (2011) 1.00
Frequent alterations of Smad signaling in human head and neck squamous cell carcinomas: a tissue microarray analysis. Oncol Res (2003) 0.96
PET with the 89Zr-labeled transforming growth factor-β antibody fresolimumab in tumor models. J Nucl Med (2011) 0.95
Identification of function for CD44 intracytoplasmic domain (CD44-ICD): modulation of matrix metalloproteinase 9 (MMP-9) transcription via novel promoter response element. J Biol Chem (2012) 0.95
Transforming growth factor beta signaling is disabled early in human endometrial carcinogenesis concomitant with loss of growth inhibition. Cancer Res (2002) 0.93
Estrogen-dependent prognostic significance of cyclooxygenase-2 expression in early-stage invasive breast cancers treated with breast-conserving surgery and radiation. Int J Radiat Oncol Biol Phys (2008) 0.93
Selective inhibitors of type I receptor kinase block cellular transforming growth factor-beta signaling. Biochem Pharmacol (2004) 0.91
Promoter-independent regulation of vimentin expression in mammary epithelial cells by val(12)ras and TGFbeta. Exp Cell Res (2007) 0.90
A novel vitamin D derivative activates bone morphogenetic protein signaling in MCF10 breast epithelial cells. Mol Pharmacol (2006) 0.85
Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma. Head Neck (2012) 0.85
Constitutive Smad linker phosphorylation in melanoma: a mechanism of resistance to transforming growth factor-β-mediated growth inhibition. Pigment Cell Melanoma Res (2011) 0.84
Luminal breast cancer metastasis is dependent on estrogen signaling. Clin Exp Metastasis (2012) 0.82
TGFbeta superfamily signaling: notes from the desert. Development (2007) 0.81
Long-term assessment of cardiac function after dose-dense and -intense sequential doxorubicin (A), paclitaxel (T), and cyclophosphamide (C) as adjuvant therapy for high risk breast cancer. Breast Cancer Res Treat (2006) 0.81
Bcl-2 antisense (G3139, Genasense) enhances the in vitro and in vivo response of Epstein-Barr virus-associated lymphoproliferative disease to rituximab. Clin Cancer Res (2003) 0.80
Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging. Pharmacol Ther (2012) 0.78
A clinically motivated 2-fold framework for quantifying and classifying immunohistochemically stained specimens. Med Image Comput Comput Assist Interv (2007) 0.76
Decentralized data sharing of tissue microarrays for investigative research in oncology. Cancer Inform (2007) 0.76
Correspondence (letter to the editor): Explanation in the text would have been desirable. Dtsch Arztebl Int (2009) 0.75
[Medical aspects of left handedness]. Med Monatsschr Pharm (2002) 0.75
[Antiemetic therapy]. MMW Fortschr Med (2010) 0.75
Five-year update of an expanded phase II study of dose-dense and -intense doxorubicin, paclitaxel and cyclophosphamide (ATC) in high-risk breast cancer. Oncology (2005) 0.75
Sequential high-dose alkylating therapy and stem cell support for high-risk stage III breast cancer. Breast J (2003) 0.75
[Otorhinolaryngology--VI: Inhalation therapy--what Celsius already knew]. Pflege Z (2002) 0.75
The RCVS codes of conduct: what's in a word? Vet Rec (2014) 0.75
[Analgesic intolerance: pathogenesis, diagnosis and treatment]. Med Monatsschr Pharm (2009) 0.75
[Otorhinolaryngology--VII: Cotton swabs have no business in ears]. Pflege Z (2002) 0.75
[Motion sickness. Findings and treatment]. Med Monatsschr Pharm (2003) 0.75
[Treatment of middle ear diseases]. Med Monatsschr Pharm (2002) 0.75
A young woman with recurrence of breast cancer. Cancer Pract (2002) 0.75
[Otorhinolaryngology--V. Hemorrhage of the ENT area requires rapid management]. Pflege Z (2002) 0.75